Product Overview
Zyvex Pharmaceuticals presents Clomid as a box of one hundred 50 mg tablets, and the active molecule is clomiphene citrate, the oldest selective estrogen receptor modulator in the recovery conversation. Pharmacy labels it for ovulation induction. Bodybuilding adopted it for a different reason: after a suppressive course the hypothalamus has stopped sending its signal, and clomiphene removes the estrogen brake on that signal so the pituitary starts releasing gonadotropins again.
The tablet is a mixture of two geometric isomers, enclomiphene and zuclomiphene, and they behave differently. The parent drug clears with a half-life of four to seven days, but zuclomiphene has been measured on urine testing at 121 days and beyond, with one study following it past 261 days in men. That single number changes how the product is planned for anyone subject to testing, because the course may be over long before the marker leaves the sample.
Nothing about the pack is an androgen. It adds no muscle, holds no fluid, and it is not a substitute for a base. Its position in a plan is strictly at the end, after the esters from Testosterone Esters or Sustanon 250 have had time to clear, and it works beside Nolvadex Tamoxifen rather than instead of it.
Dosage Protocol
Amounts and lengths come from the reference material for the substance and from the recovery pattern that dominates user practice. They are starting figures for a plan guided by blood work.
| Level | Amount | Length | Note |
| Standard recovery | 50 mg daily | 4 weeks | The pattern seen most often, taken once daily |
| Higher opening | 50-100 mg daily | 4 weeks | The larger amount is used only in the first days after a long or heavy suppression |
| Extended | 100 mg for the first days, then 50 mg | 4-6 weeks | Reserved for plans with a long-acting ester in the background |
| Female | Not a sports protocol | - | Medically it induces ovulation; it has no place in a female physique plan |
| Route | Oral tablet | Once daily | Enterohepatic recycling stretches the action beyond the half-life itself |
Timing is the part users get wrong. The tablet cannot out-run an ester that is still releasing, so the start date is set by the ester and not by the calendar. Short-acting compounds allow an earlier start than a decanoate or an undecanoate, and the first blood draw follows roughly two weeks later, once the gonadotropin response has had time to translate into testosterone.
Suggested Protocols
These are catalogue arrangements, not tested blueprints, and every one of them assumes the suppressive compounds have cleared or nearly cleared before the first tablet.
What to Expect
- The first change is on paper: luteinising hormone and follicle stimulating hormone move before total testosterone does.
- Published work in hypogonadal men records a lift of roughly 2x to 2.5x over the baseline concentration, which is a large change on a lab sheet and depends on how deep the suppression went.
- The effect holds between doses because of enterohepatic recycling and the slow-clearing isomer, so a single daily tablet is enough.
- Flushes, mood swings and disturbed sleep are the complaints users report most often, usually in the opening fortnight.
- Vision changes are uncommon but they are the reason to stop rather than to push through, and they are described in up to one in ten users.
- The tablet is not a booster for someone with a normal axis; without a suppressed starting point there is nothing for it to restore.
Side Effects and Management
Post-Cycle Therapy
This is the recovery product, so the section is the point of the page. The rule that governs everything else is that the tablet starts when the suppressive compound has cleared, not when the injections stop. A test taken three weeks into recovery should show luteinising hormone, follicle stimulating hormone and total testosterone moving in the same direction; if it does not, the answer is a longer wait or a different drug, not a bigger dose.
